HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $66 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on SpringWorks Therapeutics (NASDAQ:SWTX) and maintained a price target of $66.
August 24, 2023 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $66.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for SpringWorks Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100